Article metrics

Download PDFPDF

LB0004 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Free

 

Online download statistics by month:

Online download statistics by month: May 2022 to April 2024

AbstractFullPdf
May 20228505
Jun 202215670167
Jul 20226500105
Aug 20227380143
Sep 20226990184
Oct 2022550081
Nov 2022586090
Dec 2022440059
Jan 2023386057
Feb 2023416067
Mar 2023398034
Apr 2023345040
May 2023292038
Jun 2023301020
Jul 2023187025
Aug 2023254018
Sep 2023232015
Oct 2023203015
Nov 2023493023
Dec 202315703
Jan 2024193011
Feb 2024185011
Mar 2024155016
Apr 2024204024
Total971601251